Objective: To evaluate the efficacy and safety of Jiawei Simiao powder (JWSMP) combined with celecoxib for the treatment of acute gouty arthritis by conducting a meta-analysis of randomized controlled trials (RCTs). Methods: The Chinese National Knowledge Infrastructure Databases, Chinese Scientific Journal Database, Wanfang, Cochrane Library, EMBASE, PubMed, and Web of Science databases were searched from inception until December 2023. Continuous variables were analyzed using the mean difference (MD) for analysis, and dichotomous variables were used as risk ratios. Data with similar characteristics were pooled for meta-analysis, and heterogeneity was assessed using I2. The Cochrane Handbook was used to assess the risk of bias and quality. RevMan 5.3 software was used to perform the meta-analysis. Results: Thirteen RCTs involving 1007 patients were included in the study. The quality of the included studies was low (unclear randomization processes and insufficient blinding reporting). The group receiving JWSMP combined with celecoxib showed significantly lower levels of serum uric acid (SUA, MD = −66.32, 95% confidence interval (CI): −80.97 to −51.67, P < .001), erythrocyte sedimentation rate (ESR, MD = −6.05, 95% CI: −8.29 to −3.82, P < .001), C-reactive protein (CRP, MD = −7.39, 95% CI: −11.15, −3.63, P < .001), and joint pain score (VAS score, MD = −2.14, 95% CI: −2.4 to −1.88, P < .001) compared to celecoxib alone. Additionally, the JWSMP combined group had a higher total effective rate (risk ratio = 1.22, 95% CI: 1.14 to 1.29, P < .001) and fewer adverse compared to celecoxib alone. Conclusions JWSMP combined with celecoxib is more effective than celecoxib alone in improving the total efficacy rate, alleviating joint pain, and improving SUA, ESR, and CRP levels. JWSMP also reduced the occurrence of adverse events caused by celecoxib. However, the quality of the included studies was low, highlighting the need for further high-quality research with larger sample sizes and robust methodologies, such as double-blind randomization, to confirm these findings.

Objective To investigate the clinical significance of anti-Sj?gren′s syndrome type A antibody(SSA)and anti-Sj?gren′s syndrome type B antibody(SSB)in idiopathic inflammatory myopathies(IIM)and IIM associated interstitial disease(ILD).Methods A total of 102 patients with IIM were selected.The general information,clinical manifestations and auxiliary examinations were collected.Their positive rates of anti-SSA and anti-SSB antibodies in IIM patients were analyzed.IIM patients were divided into the SS antibody negative group(73 patients)and the SS antibody positive group(29 patients)according to the results of anti SSA and SSB antibody tests.The clinical significance of anti-SSA and anti-SSB antibodies in IIM and IIM related ILD was analyzed.Results Compared with patients in the SS antibody positive group,patients in the SS antibody negative group were more likely to experience dry mouth,increased erythrocyte sedimentation rate(ESR)and increased immunoglobulin A(IgA)levels(P＜0.05).The general situation score of the MDAAT(myositis disease activity assessment tool)was significantly higher in the SS antibody positive group than that in the SS antibody negative group(P＜0.05),and there were no significant differences in scores of other MDAAT items between the two groups(P＞0.05).There were no significant differences in the positive rate of myositis autoantibodies,recurrence rate,hormone therapy and immunosuppressive therapy between the two groups(P＞0.05).The proportion of patients treated with intravenous human immunoglobulin was higher in the SS antibody positive group than that of the SS antibody negative group(P＜0.05).Non-specific interstitial pneumonia(NSIP)was the most type of ILD in both the SS antibody negative group and the positive group,followed by usual interstitial pneumonia(UIP).Patients with IIM who were positive for anti-SSA/SSB antibodies were more likely to progress to the overlapping syndrome of combined SS.Conclusion Positive anti-SSA and anti-SSB antibodies in IIM patients are associated with dry mouth symptoms,and anti-SSA/SSB antibodies may become one of the important laboratory indicators for judging patient conditions and predicting disease outcomes.

Objective:To provide epidemiological data and clinical evidence for cosmetic adverse reactions.Methods:A retrospective clinical analysis was carried out on a total 820 outpatients (23 males and 797 females) suspected to be with cosmetic adverse reactions from January 2014 - October 2017, and average age of these patients was 7~75 (32.66±8.09) years. Suspicious cosmetics patch tests were performed in some patients. Suspicious cosmetics patch tests were performed in 687 patients.Results:Among 820 patients with cosmetic adverse reactions, women accounted for 97.20% and men accounted for 2.80%. Age distribution was most common among young people aged 21-40 years, accounting for 71.34%. The highest level of education was higher education, accounting for 59.69%. Occupational distribution was most commonly concentrated in employees and unemployed persons, accounting for 28.54% and 18.66%, respectively. A history of cosmetics allergies accounted for 17.28%. Cosmetic contact dermatitis was the most common clinical type of cosmetic adverse reactions, accounting for 92.70%. A total of 1682 suspected pathogenic cosmetics were involved. The positive rate of the cosmetic original patch test was 42.39%. Among the cosmetics with a positive patch test, moisturizing, anti-wrinkle and whitening freckle cosmetics accounted for the highest proportion, 31.59%, 15.09%, and 12.68%, respectively.Conclusions:Cosmetic contact dermatitis is the most common type of cosmetic adverse reaction. Patch testing is helpful in identifying the contact allergens in cosmetic adverse reaction.